Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19

PHASE3CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

May 21, 2020

Primary Completion Date

August 10, 2020

Study Completion Date

August 20, 2020

Conditions
COVID-19
Interventions
DRUG

Favipiravir

200 mg coated tablets

DRUG

Standard of care

"Drug: Standard of Care Standard of Care will be prescribed in accordance with the recommended treatment regimens presented in the Russian guidelines for the prevention, diagnosis and treatment of COVID-19 according to the decision of the Investigator.~Other Name: Hydroxychloroquine, chloroquine, lopinavir/ritonavir, etc."

Trial Locations (5)

Unknown

State Clinical Hospital №50, Moscow

Regional Clinic Hospital of Ryazan, Ryazan

City Hospital N40 of Kurortny District, Saint Petersburg

Medical institute Ogarev Mordovia State university, Saransk

Smolensk clinical hospital №1, Smolensk

All Listed Sponsors
lead

Promomed, LLC

OTHER

NCT04542694 - Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19 | Biotech Hunter | Biotech Hunter